Patents by Inventor Elissa Keogh

Elissa Keogh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
    Publication number: 20040037843
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare prostate cancer-associated antigent epitopes, and to develop epitope-based vaccines directed towards prostate tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
    Type: Application
    Filed: January 14, 2003
    Publication date: February 26, 2004
    Inventors: John Fikes, Alessandro Sette, John Sidney, Scott Southwood, Robert Chestnut, Esteban Celis, Elissa Keogh
  • Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
    Publication number: 20040018971
    Abstract: This invention uses our knoeledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HER2/neu epitopes, and to develop epitope-based vaccines directed towards HERS2/neu-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
    Type: Application
    Filed: October 24, 2002
    Publication date: January 29, 2004
    Inventors: John Fikes, Alessandro Sette, John Sydney, Scott Southwood, Robert Chesnut, Esteban Celis, Elissa Keogh
  • Hla class I a2 tumor associated antigen peptides and vaccine compositions
    Publication number: 20030224036
    Abstract: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
    Type: Application
    Filed: October 15, 2002
    Publication date: December 4, 2003
    Inventors: John D Fikes, Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis, Elissa A Keogh, Robert Chestnut
  • HLA class I A2 tumor associated antigen peptides and vaccine compositions
    Patent number: 6602510
    Abstract: A composition or vaccine composition comprising eight isolated epitopes consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2), KLBPVQLWV (SEQ. ID. NO: 3), SMPPPGTRV (SEQ. ID. NO: 4), KVAELVHFL (SEQ. ID. NO: 5), YLQLVFGIEV (SEQ. ID. NO: 6), RLLQETELV (SEQ. ID. NO: 7), and, VVLGVVFGI (SEQ. ID. NO: 8).
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: August 5, 2003
    Assignee: Epimmune Inc.
    Inventors: John D. Fikes, Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis, Elissa A. Keogh, Robert Chesnut